Brain fog is one of the most common complaints in modern life — and several peptides have attracted serious research attention for cognitive support. Here’s what the studies actually show about Semax, Selank, Cerebrolysin, and others.
Peptides are short chains of amino acids studied for an enormous range of biological effects — from fat loss and muscle recovery to brain function and immune support. Here’s a plain-language overview of what the research covers.
BPC-157 and GHK-Cu are two of the most-studied healing peptides, but they work very differently. Here’s a clear breakdown of what the research shows and which one fits which research goal.
Multiple peptides have been studied in the context of anxiety, stress resilience, and neuroinflammation. This guide covers the research on Selank, Semax, DSIP, KPV, and Pinealon — their mechanisms of action, published study data, and what distinguishes each compound.
Peptide half-life is one of the most important pharmacokinetic parameters in research design, yet it’s frequently misunderstood. This guide explains what half-life means for peptides, what factors influence it, and how to interpret half-life data across common research compounds.
Semaglutide and cagrilintide represent two distinct pharmacological approaches to weight management research. This comparison covers mechanism of action, clinical trial data, the CagriSema combination, and what the research suggests about their complementary effects.
Joint pain is one of the most studied research areas for peptides. BPC-157 regenerates tendons. TB-500 rebuilds tissue. GHK-Cu synthesizes collagen. KPV suppresses inflammation. This article covers what the research actually shows for each compound.
Two different peptides. Two different receptor systems. One combined effect that exceeds what either can do alone. This is why the CJC-1295 No DAC and Ipamorelin blend has become one of the most studied growth hormone secretagogue combinations in research.
Semaglutide changed obesity research. Retatrutide may have changed it again. Here is what the clinical data actually shows when you put a single GLP-1 agonist head-to-head against a triple receptor agonist — and why the difference matters.
A research comparison of tirzepatide (dual GIP/GLP-1 agonist) and retatrutide (triple GIP/GLP-1/glucagon agonist) — covering mechanisms, clinical trial efficacy data, metabolic effects, side effect profiles, and what the evidence suggests about each compound’s research potential.
